A novel nanoparticulate system for sustained delivery of acid-labile lansoprazole

Colloids and Surfaces B: Biointerfaces

Volumn 111, Issue , 2013, Pages 453-459

  Alai, Milind Sadashiv ^a   Lin, Wen Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Acid labile drug; Eudragit RS100; Lansoprazole; Nanoparticles; Sustained release

Indexed keywords

ACID-LABILE; EMULSION-SOLVENT EVAPORATION METHOD; ENCAPSULATION EFFICIENCY; EUDRAGIT; LANSOPRAZOLE; NANOPARTICULATE SYSTEM; POLYMER CONCENTRATIONS; SUSTAINED RELEASE;

DRUG DELIVERY; DRUG PRODUCTS; EMULSIFICATION; EMULSIONS; ENCAPSULATION; PARTICLE SIZE; POLYMERS; RATE CONSTANTS;

NANOPARTICLES;

EUDRAGIT RS; LANSOPRAZOLE; NANOCARRIER; SOLVENT; ACID; ACRYLIC ACID RESIN; NANOPARTICLE; POLYMER; SOLUTION AND SOLUBILITY;

ARTICLE; CHEMICAL COMPOSITION; CHEMICAL PROCEDURES; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOEMULSION; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLVENT EVAPORATION; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY; ZETA POTENTIAL; CHEMISTRY; DRUG DELIVERY SYSTEM; KINETICS; SOLUTION AND SOLUBILITY; ULTRASTRUCTURE;

ACIDS; ACRYLIC RESINS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG DELIVERY SYSTEMS; KINETICS; LANSOPRAZOLE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; SOLUTIONS; SOLVENTS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84880436910     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.06.035     Document Type: Article

References (29)

1. Singh M.N., Yadav H.K.S., Ram M., Shivakumar H.G. Freeze dried chitosan/poly-(glutamic acid) microparticles for intestinal delivery of lansoprazole. Curr. Drug Deliv. 2012, 9:95-104.
2. Satoh H. Discovery of lansoprazole and its unique pharmacological properties independent from anti-secretory activity. Curr. Pharm. Design 2013, 19:67-75.
3. Shimura S., Hamamoto N., Yoshino N., Kushiyama Y., Fujishiro H., Komazawa Y., Furuta K., Ishihara S., Adachi K., Kinoshita Y. Diarrhea caused by proton pump inhibitor administration: comparisons among lansoprazole, rabeprazole, and omeprazole. Curr. Ther. Res. Clin. E 2012, 73:112-120.
4. Alai M., Lin W.J. A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. J. Microencapsul. 2013, 1:11. 10.3109/02652048.2012.758180.
5. Missaghi S., Young C., Fegely K., Rajabi-Siahboomi A.R. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies. Drug Dev. Ind. Pharm. 2010, 36:180-189.
6. He W., Yang M., Fan J.H., Feng C.X., Zhang S.J., Wang J.X., Guan P.P., Wu W. Influences of sodium carbonate on physicochemical properties of lansoprazole in designed multiple coating pellets. AAPS PharmSciTech 2010, 11:1287-1293.
7. Shimizu T., Kameoka N., Iki H., Tabata T., Hamaguchi N., Igari Y. Formulation study for lansoprazole fast-disintegrating tablet. II. Effect of triethyl citrate on the quality of the products. Chem. Pharm. Bull. (Tokyo) 2003, 51:1029-1035.
8. Katz P.O., Koch F.K., Ballard E.D., Bagin R.G., Gautille T.C., Checani G.C., Hogan D.L., Pratha V.S. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment. Pharmacol. Ther. 2007, 25:197-205.
9. Yuan Y., Hunt R.H. Evolving issues in the management of reflux disease?. Curr. Opin. Gastroenterol. 2009, 25:342-351.
10. Wang X.Q., Zhang Q. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 2012, 82:219-229.
11. Singh S. Nanomedicine-nanoscale drugs and delivery systems. J. Nanosci. Nanotechnol. 2010, 10:7906-7918.
12. Sinha B., Mukherjee B., Pattnaik G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine 2013, 9:94-104.
13. ® RS100 nanoparticles and solid dispersions. Powder Technol. 2012, 219:211-216.
14. Khalil N.M., do Nascimento T.C., Casa D.M., Dalmolin L.F., de Mattos A.C., Hoss I., Romano M.A., Mainardes R.M. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B: Biointerfaces 2013, 101:353-360.
15. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B: Biointerfaces 2010, 75:1-18.
16. Agnihotri S.M., Vavia P.R. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009, 5:90-95.
17. Cortesi R., Mischiati C., Borgatti M., Breda L., Romanelli A., Saviano M., Pedone C., Gambari R., Nastruzzi C. Formulations for natural and peptide nucleic acids based on cationic polymeric submicron particles. AAPS PharmSci. 2004, 6:E2.
18. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15:25-35.
19. ® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Colloids Surf. B: Biointerfaces 2013, 102:441-449.
20. Shiino K., Yasunori I., Fujinami Y., Itai S. Preparation and evaluation of granules with pH-dependent release by melt granulation. Int. J. Pharm. 2012, 431:70-77.
21. Krishnamachari Y., Madan P., Lin S.S. Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int. J. Pharm. 2007, 338:238-247.
22. Zvonar A., Kristl J., Kerc J., Grabnar P.A. High celecoxib-loaded nanoparticles prepared by a vibrating nozzle device. J. Microencapsul. 2009, 26:748-759.
23. Fu X., Ping Q., Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J. Microencapsul. 2005, 22:57-66.
24. Mainardes R.M., Evangelista R.C. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J. Microencapsul. 2005, 22:13-24.
25. Mccarron P.A., Donnelly R.F., Marouf W. Celecoxib-loaded poly(d,l-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J. Microencapsul. 2006, 23:480-498.
26. Poletto F.S., Silveira R.P., Fiel L.A., Donida B., Rizzi M., Guterres S.S., Pohlmann A.R. Size-control of poly(epsilon-caprolactone) nanospheres by the interface effect of ethanol on the primary emulsion droplets. J. Nanosci. Nanotechnol. 2009, 9:4933-4941.
27. Bhagav P., Upadhyay H., Chandran S. Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation. PharmSciTech 2011, 12:1087-1101.
28. Sun W.Z., Lin W.J., Alai M.S. Preparation of microparticles for acid-labile lansoprazole by solvent evaporation method combined with a spray drying process. J. Food Drug Anal. 2012, 20:438-445.
29. Elzoghby A.O., Samy W.M., Elgindy N.A. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm. Res. 2013, 30:512-522.